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High-sensitivity cardiac troponin
I assays in the diagnosis of acute
myocardial infarction
Andrew R Chapman, David E Newby, Nicholas L Mills
Chest pain is one of the most common
presenting symptoms in patients attending
the emergency department; yet, less than
one in ﬁve patients receive a ﬁnal diagno-
sis of acute myocardial infarction.1 In
patients without ST segment elevation,
early exclusion of acute coronary syn-
drome has the potential to reduce health-
care expenditure in a population with
signiﬁcant resource implications. Previous
approaches were hindered by the per-
formance of contemporary troponin
assays, which used a decision threshold
for the diagnosis of myocardial infarction
based on assay imprecision rather than a
deﬁned upper reference limit from a
healthy population.2 High-sensitivity
cardiac troponin assays were ﬁrst intro-
duced into clinical practice in Europe,
Canada, Australia and New Zealand in
2010, and are deﬁned by their ability to
measure circulating troponin in the major-
ity of healthy individuals, allowing accur-
ate identiﬁcation of the reference range,
and demonstrating an acceptable level of
imprecision at the 99th centile (≤10%
coefﬁcient of variation): the recom-
mended decision threshold for acute myo-
cardial infarction in clinical practice.3
Importantly, international guidelines now
recommend these assays may be used to
rule out the diagnosis of myocardial
infarction at an earlier stage which may
prevent unnecessary hospital admission.3 4
However, as there are a number of differ-
ent high-sensitivity cardiac troponin assays
from different manufacturers, each with
their own strengths and limitations, it is
essential clinicians are aware of their
unique characteristics to allow optimal
and safe use in clinical practice.
In their expert consensus document,
Tan et al5 provide a systematic approach
to the optimal use of high-sensitivity
cardiac troponin I assays for the
Asia-Paciﬁc region, including a hybrid
diagnostic algorithm for both rule-in and
rule-out of myocardial infarction. In line
with other international guidelines, they
recommend cardiac troponin as the bio-
marker of choice in patients with sus-
pected acute coronary syndrome, with
concentrations measured using a high-
sensitivity assay and reported in ng/L to
encourage consistency and minimise inter-
pretation error. To conﬁrm or exclude a
diagnosis of myocardial infarction, Tan
et al recommend serial cardiac troponin
testing in all patients, although alternative
approaches do exist.
The latest European Society of
Cardiology guidelines allow rule-out of
acute coronary syndrome in patients with
at least 6 hours of symptoms who are
<99th centile on presentation to hos-
pital.4 However, there are concerns that
the 99th centile is not the optimal thresh-
old to safely rule out myocardial infarc-
tion in the absence of serial testing, with
recent studies showing this approach
missed a number of index diagnoses.6
There are now a number of validated
studies demonstrating a single high-
sensitivity cardiac troponin I or T test on
presentation may reliably exclude the
diagnosis of myocardial infarction with
high negative predictive value. Such
approaches use a cardiac troponin deci-
sion threshold far below the 99th centile,
often at or close to the limit of detection,
exploiting the robust performance of
high-sensitivity assays. For example, a
high-sensitivity cardiac troponin I concen-
tration <5 ng/L gave a negative predictive
value of 99.6% in 6304 consecutive
patients presenting with suspected acute
coronary syndrome.1 Additional strategies
using lower concentrations of cardiac
troponin I such as the limit of detection
(1.9 ng/L) or higher have been proposed.7
These strategies reduce the number of
patients eligible for rule-out and may
reduce the absolute number of missed
cases. Whether single rule-out strategies
using low concentrations of cardiac tropo-
nin are safe and effective in clinical prac-
tice require further prospective evaluation
in randomised controlled trials. Until then,
serial testing strategies will remain a critical
component of the evaluation of patients
with suspected acute coronary syndrome.
Tan et al recommend serial testing on
presentation and at 3 hours in line with
other international guidelines.3 4 In this
setting, the authors suggest a change of
>50% at 3 hours is indicative of a patient
at high risk of acute myocardial infarction.
This is broadly in line with prior recom-
mendations from the European Society of
Cardiology Working Group on Acute
Cardiac Care, and is thought to provide
sufﬁcient clarity from both biological and
analytical variation. However, the subtle
difference in the algorithm proposed by
Tan et al is the recognition of the import-
ance of changes in cardiac troponin con-
centration within the normal reference
range. For example, consider a male
patient with a high-sensitivity cardiac
troponin I concentration of 10 ng/L at
presentation and a concentration of
25 ng/L at 3 hours. Despite a >50%
change in concentration, they would be
ruled out by the 3-hour diagnostic
pathway of the European Society of
Cardiology if they had no ongoing chest
pain and had a low GRACE score (<140).
In the pathway proposed by Tan et al, this
patient would be considered at high risk
of myocardial infarction and would be
recommended for further testing. This
will reduce the likelihood of missed index
diagnoses. While Tan et al recommend a
relative change in cardiac troponin con-
centration, absolute changes in cardiac
troponin concentration may also be
informative at lower concentrations. An
absolute change of >3 ng/L at 3 hours in
those patients with troponin concentra-
tions ≤99th centile at presentation identi-
ﬁes patients with increasing cardiac
troponin concentrations who would
beneﬁt from further testing at 6 hours.6
The latest iteration of the European
Society of Cardiology guidelines includes
an alternative testing strategy using a pres-
entation and 1-hour rule-out pathway
with thresholds of cardiac troponin below
the 99th centile.4 This strategy was
derived and validated using a high-
sensitivity cardiac troponin T assay, with
secondary derivation of thresholds for
cardiac troponin I, and has a high negative
predictive value. As noted by Tan et al,
laboratory turnaround times in some
centres may prevent a clinician having a
presentation troponin result within
1 hour, which they suggest may preclude
use of this approach. One could argue
that a serial sample may still be obtained
at 1 hour although a delay in clinical
decision-making would be necessary until
both results were available. Current
debate focuses on whether the thresholds
for change in cardiac troponin I
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concentration as proposed in the 1-hour
pathway of the European Society of
Cardiology (≥2 ng/L) may be reliably dis-
tinguished from analytical variability,
since as many as 50% of patients without
acute coronary syndrome can have a
change of 2 ng/L on serial testing.
While one of the major advantages of
using a high-sensitivity assay is the earlier
rule-out of myocardial infarction, accurate
identiﬁcation of patients with myocardial
infarction is equally important as this
may facilitate earlier treatment and trans-
fer to an appropriate care setting. The
Asia-Paciﬁc consortium proposes a rule-in
threshold for myocardial infarction of 10
times the upper limit of normal (260 ng/L
for the Abbott ARCHITECTSTAT high-
sensitivity troponin I assay). This threshold
was recommended by the Asia-Paciﬁc con-
sensus group, as the current European
Society of Cardiology threshold of 52 ng/L
only has a positive predictive value of
84%.5 The authors quote a speciﬁcity of
98% for their rule-in threshold of 260 ng/L,
but the source of this is unclear. As a rule-in
threshold will lead to treatment for myocar-
dial infarction, the authors’ approach for
maximising positive predictive value is justi-
ﬁed although any patient with elevation
>99th centile on presentation still requires
serial testing to demonstrate a rise and fall:
an integral component of the deﬁnition of
myocardial infarction.
The authors recommend clinicians
adopt gender-speciﬁc thresholds when
using the Abbott ARCHITECTSTAT high-
sensitive cardiac troponin I assay, where
concentrations in men are two-fold higher
than those in women. Use of gender-
speciﬁc thresholds identify women at
higher risk of future myocardial infarction
or cardiac death, and there is the potential
for outcomes to be improved.8
Importantly, Tan et al highlight this differ-
ence in 99th centile concentration
between men and women is consistent
across different populations, despite the
inﬂuence of age, renal function, ethnicity
and specimen type.3
In settings where access to laboratory
facilities is limited, Tan et al acknowledge
there may be a role for contemporary
point-of-care testing. It is imperative that
patients with suspected acute coronary
syndrome are not ‘ruled out’ on the basis
of a normal or undetectable point-of-care
result until repeat testing has been per-
formed at 6 hours or the patient has
undergone formal laboratory testing. We
ﬁrmly agree with the authors’ recommen-
dation for an ongoing programme of edu-
cation for those clinicians who are
requesting and interpreting cardiac tropo-
nin tests. This is of greatest importance
for new or rotating clinical staff who may
be unfamiliar with the cardiac troponin
assay in use at their new institution, as
cardiac troponin decision thresholds and
concentrations are not interchangeable
between different assay types.
In summary, Tan et al should be com-
mended for compiling a large volume of
evidence into a clear and concise series of
recommendations for the clinician who
may be seeking to introduce high-
sensitivity cardiac troponin testing into
clinical practice. In this constantly evol-
ving ﬁeld, it is important that all clinicians
remain abreast of the latest developments,
with further changes in the recommended
strategy for rule-out of acute coronary
syndrome likely in the fourth iteration of
the universal deﬁnition of myocardial
infarction in 2018.
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